CEL-SCI's Phase 3 Population Analysis For Confirmatory Registration Study In Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence In Clinical Results; Multikine, A Cancer Immunotherapy, Cut The 5-Year Risk Of Death By Half Compared To Control In Its Target Population
Author: Benzinga Newsdesk | July 26, 2024 08:24am
- Multikine, a true first-line cancer immunotherapy, cut the 5-year risk of death by half compared to control in its target population
- Bias analysis conducted in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study
- Detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms, no bias found, supporting confidence in Multikine's efficacy results
CEL-SCI Corporation (NYSE:CVM) today reported positive results from a bias analysis conducted for its concluded Phase 3 study of Multikine (Leukocyte Interleukin, Injection)* in the treatment of head and neck cancer. Conducting a bias analysis is a standard process used to identify, assess, and address potential sources of bias that could influence the outcomes and interpretations of study results. The goal of a bias analysis is to ensure that the trial's findings are reliable, the conclusions are valid, and to minimize the risk that bias has distorted the results.
Posted In: CVM